| 2.24 -0.02 (-0.88%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.73 | 1-year : | 2.99 |
| Resists | First : | 2.34 | Second : | 2.55 |
| Pivot price | 2.35  |
|||
| Supports | First : | 1.99 | Second : | 1.65 |
| MAs | MA(5) : | 2.29 |
MA(20) : | 2.34  |
| MA(100) : | 2.4 |
MA(250) : | 1.95 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 21.5 |
D(3) : | 28.4 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 3.24 | Low : | 1.29 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CGEN ] has closed above bottom band by 10.0%. Bollinger Bands are 54.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.3 - 2.32 | 2.32 - 2.33 |
| Low: | 2.18 - 2.2 | 2.2 - 2.21 |
| Close: | 2.21 - 2.24 | 2.24 - 2.27 |
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.
Wed, 29 Jul 2026
Compugen Ltd (CGEN) Institutional Confidence - TradingKey
Wed, 29 Jul 2026
Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Wed, 29 Jul 2026
CGEN|Compugen Ltd|Price:2.265|Chg%:-0.115 - TradingKey
Mon, 27 Jul 2026
CGEN|Compugen Ltd|Price:2.235|Chg%:-0.025 - TradingKey
Mon, 27 Jul 2026
CGEN|Compugen Ltd|Price:2.235|Chg%:-0.025 - TradingKey
Sun, 26 Jul 2026
Compugen Ltd (CGEN) Cash Flow - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 15.4 (%) |
| Shares Short | 3,030 (K) |
| Shares Short P.Month | 2,870 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 47.9 % |
| Operating Margin | -414.4 % |
| Return on Assets (ttm) | 14.6 % |
| Return on Equity (ttm) | 45.7 % |
| Qtrly Rev. Growth | -4.7 % |
| Gross Profit (p.s.) | 0.67 |
| Sales Per Share | 0.76 |
| EBITDA (p.s.) | 0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 5.89 |
| PEG Ratio | 1.2 |
| Price to Book value | 2.21 |
| Price to Sales | 2.91 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|